Table 2.
Clinical features of PDAC patients in TCGA-PAAD dataset
| Clinical features | Mean+SD |
|---|---|
| Follow up time (day) | 538.05 ± 418.09 |
| Risk Score | 1.75 ± 0.32 |
| Age | 64.70 ± 11.00 |
| Size (cm) | 3.74 ± 1.37 |
| N (%) | |
| Survival status | |
| Alive | 62 (43.97%) |
| Dead | 79 (56.03%) |
| KRAS mutation | |
| Wildtype | 15 (10.64%) |
| Mutant | 126 (89.36%) |
| TP53 mutation | |
| Wildtype | 43 (30.50%) |
| Mutant | 98 (69.50%) |
| CDKN2A mutation | |
| Wildtype | 76 (53.90%) |
| Mutant | 65 (46.10%) |
| SMAD4 mutation | |
| Wildtype | 107 (75.89%) |
| Mutant | 34 (24.11%) |
| BRCA1 mutation | |
| Wildtype | 135 (95.74%) |
| Mutant | 6 (4.26%) |
| BRCA2 mutation | |
| Wildtype | 139 (98.58%) |
| Mutant | 2 (1.42%) |
| Sex | |
| Male | 75 (53.19%) |
| Female | 66 (46.81%) |
| Subtype | |
| Pancreas-Adenocarcinoma Ductal Type | 128 (90.78%) |
| Pancreas-Adenocarcinoma-Other Subtype | 13 (9.22%) |
| Grade | |
| G1 | 18 (12.77%) |
| G2 | 80 (56.74%) |
| G3 | 42 (29.79%) |
| G4 | 1 (0.71%) |
| T | |
| T1 | 5 (3.55%) |
| T2 | 14 (9.93%) |
| T3 | 118 (83.69%) |
| T4 | 3 (2.13%) |
| Not available | 1 (0.71%) |
| N | |
| N0 | 36 (25.53%) |
| N1 | 103 (73.05%) |
| Not available | 2 (1.42%) |
| M | |
| M0 | 67 (47.52%) |
| Mx | 74 (52.48%) |
| AJCC stage | |
| IA | 4 (2.84%) |
| IB | 7 (4.96%) |
| IIA | 24 (17.02%) |
| IIB | 101 (71.63%) |
| III | 2 (1.42%) |
| Not available | 3 (2.13%) |
| Residual tumor | |
| R0 | 76 (53.90%) |
| R1 | 47 (33.33%) |
| R2 | 5 (3.55%) |
| Not available | 13 (9.22%) |
| Site | |
| Head of Pancreas | 113 (80.14%) |
| Body of Pancreas | 11 (7.80%) |
| Tail of Pancreas | 8 (5.67%) |
| Others | 9 (6.38%) |
| Initial pathologic diagnosis method | |
| Tumor resection | 88 (62.41%) |
| Tissue Biopsy | 25 (17.73%) |
| Cytology (e.g. Peritoneal or pleural fluid) | 18 (12.77%) |
| Fine Needle Aspiration Biopsy | 5 (3.55%) |
| Not available | 5 (3.55%) |
| Surgical treatment | |
| Whipple | 112 (79.43%) |
| Distal Pancreatectomy | 17 (12.06%) |
| Distal Pancreatectomy & laporoscopy followed by Hand-assisted and Splenectomy | 1 (0.71%) |
| Subtotal pancreatectomy and splenectomy and cholecystectomy | 1 (0.71%) |
| Radical pancreaticoduodenectomy | 4 (2.84%) |
| Total Pancreatectomy | 2 (1.42%) |
| Endoscopic Retrograde Cholangiopancreaticography | 1 (0.71%) |
| Not available | 3 (2.13%) |
| History of neoadjuvant treatment | |
| No | 141 (100.00%) |
| History of chemotherapy | |
| No | 43 (30.50%) |
| Yes | 98 (69.50%) |
| History of radiation therapy | |
| No | 81 (57.45%) |
| Yes | 28 (19.86%) |
| Not available | 32 (22.70%) |
| History of targeted molecular therapy | |
| No | 35 (24.82%) |
| Yes | 97 (68.79%) |
| Not available | 9 (6.38%) |
| Tobacco smoking history | |
| Lifelong Non-smoker | 50 (35.46%) |
| Current smoker | 16 (11.35%) |
| Current reformed smoker for > 15 years | 23 (16.31%) |
| Current reformed smoker for ≤ 15 years | 21 (14.89%) |
| Current reformed smoker, duration not specified | 7 (4.96%) |
| Not available | 24 (17.02%) |
| Alcohol drinking history | |
| No | 49 (34.75%) |
| Yes | 81 (57.45%) |
| Not available | 11 (7.80%) |
| History of chronic pancreatitis | |
| No | 103 (73.05%) |
| Yes | 13 (9.22%) |
| Not available | 25 (17.73%) |
| History of diabetes | |
| No | 90 (63.83%) |
| Yes | 31 (21.99%) |
| Not available | 20 (14.18%) |
| History of prior malignancy | |
| No | 128 (90.78%) |
| Yes | 13 (9.22%) |